Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
Hidenori ToyodaMasanori AtsukawaTsunamasa WatanabeMakoto NakamutaHaruki UojimaAkito NozakiKoichi TakaguchiShinichi FujiokaEtsuko IioToshihide ShimaTakehiro AkahaneShinya FukunishiToru AsanoKojiro MichitakaKunihiko TsujiHiroshi AbeShigeru MikamiHironao OkuboTomomi OkuboNoritomo ShimadaToru IshikawaAkio MoriyaJoji TaniAsahiro MorishitaChikara OgawaYoshihiko TachiHiroki IkedaNaoki YamashitaSatoshi YasudaMakoto ChumaAkemi TsutsuiAtsushi HiraokaTadashi IkegamiTakuya GendaAkihito TsubotaTsutomu MasakiYasuhito TanakaKatsuhiko IwakiriTakashi KumadaPublished in: Journal of gastroenterology and hepatology (2019)
The 12-week GLE/PIB regimen was well-tolerated with high virologic efficacy in patients with cirrhosis, experience of DAA, or HCV genotype 3; tolerability and SVR rate were comparable with those of DAA-naïve, non-cirrhotic, non-genotype 3 patients who underwent 8-week regimen.